Ambrx Biopharma, Inc. (AMAM)

NYSE: AMAM · IEX Real-Time Price · USD
3.85
-0.15 (-3.75%)
May 20, 2022 4:00 PM EDT - Market closed

Company Description

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform.

Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.

The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers.

In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell.

Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health.

The company was incorporated in 2003 and is headquartered in La Jolla, California.

Ambrx Biopharma, Inc.
CountryUnited States
Founded2003
IPO DateJun 18, 2021
IndustryBiotechnology
SectorHealth Care
Employees81

Contact Details

Address:
10975 North Torrey Pines Road
La Jolla, CA 92037
United States
Phone858 875 2400
Websiteambrx.com

Stock Details

Ticker SymbolAMAM
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code1836056

Key Executives

NamePosition
Dr. Feng Tian Ph.D.President, Member of Scientific Advisory Board, Chief Executive Officer and Chairman
Sonja Nelson CPAChief Financial Officer
Dr. Shawn Shao-Hui Zhang Ph.D.Executive Vice President of Research & Development Operations and GM of Ambrx China
Dr. Janice Lu M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
May 17, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 26, 2022S-8Securities to be offered to employees in employee benefit plans
Apr 26, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Apr 26, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 10, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 14, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 11, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 9, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 8, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 7, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings